Coronary Artery Disease, In-Stent Restenosis
Conditions
Keywords
Drug-Coated Balloon
Brief summary
The study is a Prospective, Randomized, Non-Inferiority Trial to Determine the Safety and Efficacy of the BA9™ Drug Coated Balloon for the Treatment of In-Stent Restenosis. It is a First-in-Man Trial.
Detailed description
This clinical trial will serve as a first-in-human (FIH) experience for the BA9™ DCB in a population of patients with coronary artery disease who have an indication for interventional treatment of in-stent restenosis (ISR) in a bare-metal stent (BMS) or drug-eluting stent (DES). The study uses a prospective, multi-center, single blind, randomized controlled trial design to enroll 195 patients. The study will seek to prove that the BA9-DCB is non-inferior to the approved CE marked Sequent Please® Paclitaxel Coated Balloon with respect to % Diameter Stenosis and has similar safety characteristics.
Interventions
DEVICEBiolimus A9 Drug Coated Balloon
A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
DEVICESeQuent Please Paclitaxel Drug Coated Balloon
A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
Sponsors
Biosensors Europe SA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
The subject will be blinded to the study treatment.
Intervention model description
Patients who meet all the eligibility criteria will be randomized 2:1 to receive treatment with either a BA9-DCB or a Sequent Please® Paclitaxel Coated Balloon.
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients presenting with in-stent restenosis (ISR) and clinical symptoms of ischemia and/or (i) evidence of ischemia on non-invasive testing or (ii) hemodynamically relevant lesion defined by FFR ≤ 0.80 or iFR ≤ 0.89 or \> 90% stenosis. * Patient presenting with a lesion that can be fully covered with one DCB length. - Patients can have up to two index lesions with ISR, which can both be treated and evaluated. * Patient has provided written informed consent * Age ≥ 18 years. * Patient is willing and able to comply with the study procedures and follow-up.
Exclusion criteria
* Patient presents with a ST-elevation myocardial infarction (STEMI) or had an acute MI within 48 hours prior to presentation (according to the universal definition of myocardial infarction). * Patient with acute cardiac decompensation or acute cardiogenic shock * Documented left ventricular ejection fraction (LVEF) ≤ 30% * Patient with impaired renal function (glomerular filtration rate \< 80 mL/min/1.73 m2). * More than 2 epicardial vessels requiring revascularization * Significant left main stenosis (by visual estimation) or an ISR located in the left main (LM). * Patient has an ISR lesion that cannot be covered with one DCB length. * Patient has an ISR in the target segment in a stent of a smaller diameter than 2.5mm. * Severe calcification that might prevent a sufficient expansion of the DCB, if not pre-treated with rotablation or a shockwave application device. * Known hypersensitivity or contraindication to biolimus, paclitaxcel, aspirin, thienopyridines, or iodinated contrast that cannot be pre-treated. * Pregnant and/or breast-feeding females or females who intend to become pregnant during the time of the study. * Subject currently enrolled in other investigational device or drug trial in which the primary endpoint has not yet been reached. * Anticipated difficulties to complete the angiographic follow-up study. * Patient with a life expectancy of less than 12 months. * Patients lacking mental capacity (i.e. patients suffering from dementia and others) to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Diameter Stenosis (DS) | 6 months | Percent DS of the target segment assessed by quantitative coronary angiography (QCA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Target lesion failure | 1 month, 6 months, 1 year and 2 years | Taget lesion failure defined as a composite of cardiovascular death, any target vessel myocardial infarction, coronary artery bypass graft and clinically driven target lesion revascularization |
| Target vessel failure | 1 month, 6 months, 1 year and 2 years | Target vessel failure defined as a composite of cardiovascular death, any target vessel myocardial infarction, and clinically driven target vessel revascularization |
Countries
Germany, Ireland, Italy, Spain, United Kingdom
Outcome results
None listed